BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29145599)

  • 1. A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease.
    Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    J Crohns Colitis; 2018 Feb; 12(3):298-305. PubMed ID: 29145599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.
    Yarur AJ; Kubiliun MJ; Czul F; Sussman DA; Quintero MA; Jain A; Drake KA; Hauenstein SI; Lockton S; Deshpande AR; Barkin JS; Singh S; Abreu MT
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1118-24.e3. PubMed ID: 25562796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine.
    Armstrong L; Sharif JA; Galloway P; McGrogan P; Bishop J; Russell RK
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1106-14. PubMed ID: 21929546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.
    Gao X; Zhang FB; Ding L; Liu H; Wang XD; Chen BL; Bi HC; Xiao YL; Zhao LZ; Chen MH; Huang M; Hu PJ
    Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):958-64. PubMed ID: 22664938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease.
    Luber RP; Dawson L; Munari S; Kariyawasam VC; Martin C; Gibson PR; Sparrow MP; Ward MG
    J Gastroenterol Hepatol; 2021 Apr; 36(4):990-998. PubMed ID: 32881046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study.
    Meijer B; Wilhelm AJ; Mulder CJJ; Bouma G; van Bodegraven AA; de Boer NKH
    Ther Drug Monit; 2017 Aug; 39(4):399-405. PubMed ID: 28489727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between 6-thioguanine nucleotide levels and preventing production of antibodies to infliximab in patients with inflammatory bowel disease.
    Phillips J; Leary S; Tyrrell-Price J
    BMJ Open Gastroenterol; 2023 Jun; 10(1):. PubMed ID: 37328288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases.
    Yarur AJ; Gondal B; Hirsch A; Christensen B; Cohen RD; Rubin DT
    J Clin Gastroenterol; 2018 Jul; 52(6):537-544. PubMed ID: 28723860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis.
    Wusk B; Kullak-Ublick GA; Rammert C; von Eckardstein A; Fried M; Rentsch KM
    Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1407-13. PubMed ID: 15618853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.
    Dervieux T; Meyer G; Barham R; Matsutani M; Barry M; Boulieu R; Neri B; Seidman E
    Clin Chem; 2005 Nov; 51(11):2074-84. PubMed ID: 16166171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
    Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
    Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab.
    Yarur AJ; McGovern D; Abreu MT; Cheifetz A; Papamichail K; Deepak P; Bruss A; Beniwal-Patel P; Dubinsky M; Targan SR; Melmed GY
    Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2908-2917.e10. PubMed ID: 36280102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
    J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
    Spencer E; Norris E; Williams C; Dubinsky MC
    Inflamm Bowel Dis; 2019 Jan; 25(1):142-149. PubMed ID: 29920603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease.
    Poon SS; Asher R; Jackson R; Kneebone A; Collins P; Probert C; Dibb M; Subramanian S
    J Crohns Colitis; 2015 Aug; 9(8):640-6. PubMed ID: 25968584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.
    Wall GC; Muktar H; Effken C; Mahajan PB
    Pharmacotherapy; 2018 Feb; 38(2):259-270. PubMed ID: 29197117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.